Clinical Research Directory

Inclusion Criteria: * Age \> 18 years * Histological diagnosis of advanced stage NSCLC * Histotype adenocarcinoma and squamous carcinoma * ECOG PS \<2 * Known PDL-1 stage * Measurable disease * Availability of tumor tissue * No evidence of molecular drivers * Written informed consent (to the study and data processing) For the second cohort in addition to the precedents it is included * Diagnosis of limited or locally advanced NSCLC deemed resectable For the third cohort in addition to the precedents it is included * patients candidates for surgery for non-small cell lung cancer Exclusion Criteria: * Contraindications to immunotherapy * Unavailability of tumor tissue * Histotype with neuroendocrine or mixed component For the second cohort * Contraindication to immunotherapy * Histotype with neuroendocrine or mixed component * Locally advanced disease candidate for concomitant chemo-radiotherapy treatment For the third cohort * previously treated patients